TCS launches ADD Site Feasibility Platform

01 Aug 2019 Evaluate

Tata Consultancy Services (TCS) has launched the Advanced Drug Development (ADD) Site Feasibility Platform, which provides life sciences companies with a single, integrated platform that digitizes the site selection and activation processes, and facilitates data-driven decision-making while assessing site feasibility for multi-site clinical trials.

TCS' Site Feasibility Platform, the latest addition to the ADD suite of cloud-based clinical platforms, addresses this critical problem currently faced by life sciences companies, by leveraging the power of digital technologies to drive superior clinical outcomes.

Moreover, the platform is fully integrated with the TCS Connected Clinical Trials e-Survey Platform, providing customers with an end-to-end solution for conducting site surveys and analyzing the survey responses.

Tata Consultancy Services is an IT services, consulting and business solutions provider that has been partnering with the world’s largest businesses in their transformation journeys for the last fifty years.


TCS Share Price

3229.15 -18.35 (-0.57%)
31-Dec-2025 09:52 View Price Chart
Peers
Company Name CMP
TCS 3229.15
Infosys 1614.85
HCL Tech. 1622.80
Wipro 262.25
Tech Mahindra 1599.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×